Boryung Corporation produces and sells pharmaceutical products in South Korea. The company offers cardiovascular products, anticancer products, gastrointestinal products, and API's. It also exports its products to approximately 50 countries on 6 continents, including Japan, China, the Southeast Asia, the Middle East, Europe, South America, and Africa. The company was formerly known as Boryung Pharmaceutical Co., Ltd. and changed its name to Boryung Corporation in March 2022. Boryung Corporation was founded in 1957 and is based in Seoul, South Korea.

Boryung Corporation

Boryung is a pharmaceutical company based in South Korea that develops and manufactures pharmaceutical products.

Metric
Company Name	Boryung Corporation
Symbol	3.85K
MSH ID	KR:CO:BORYUNG
Market	STOCKS
Sector	Healthcare
Industry	Drug Manufacturers - Specialty & Generic
Country	KR
Stage
Employee Count	1.40K
Website	boryung.co.kr
LinkedIn	%EC%A3%BC-%EB%B3%B4%EB%A0%B9
Founders

Metric
Market Cap	483.22M
Enterprise Value
Monthly Web Traffic	79.46K
Web Traffic Growth	0.46
Valuation
Raised Capital

Metric
Revenue	603.92M
Revenue (LTM)
Revenue (NTM)
Gross Profit	234.13M
EBITDA	78.75M
Operating Income	47.56M
Net Income	28.24M
EPS	0.43
Diluted EPS	0.43
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.57
Operating Profit Margin	0.08
EBITDA Margin	0.13
Net Profit Margin	0.07
Return on Equity	0.12
Return on Assets	0.06
Return on Capital Employed	0.10

KR:CO:BORYUNG

Boryung

Last Close

10,140.00

25/11 06:30

Market Cap

687.64B

Beta: -

Volume Today

142.03K

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	21.78
P/B Ratio	1.13
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	1.01
EV Multiple	3.81

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding	203.40
Operating Cycle	274.65
Cash Conversion Cycle	181.12
Asset Turnover	0.96

Metric
Operating Cash Flow	29.66M
Free Cash Flow	13.26M
Cash Flow to Debt	0.40
Operating Cash Flow/Sales	0.09
Free Cash Flow Yield	-0.16

Metric
Cash & Equivalents	11.58M
Accounts Receivable	-14.15M
Inventory	133.35M
Goodwill	2.60M
Debt to Capitalization	0.27
Debt to Assets
Current Ratio	1.73
Quick Ratio	0.92

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.00
R&D to Revenue	0.04
SG&A to Revenue	0.24